Literature DB >> 12412672

Chlamydia pneumoniae immunoglobulin A reactivation and airway inflammation in acute asthma.

P A B Wark1, S L Johnston, J L Simpson, M J Hensley, P G Gibson.   

Abstract

Infection with Chlamydia pneumoniae can trigger acute asthma and is associated with severe chronic asthma. The aim of the present study was to examine the relationship between airway inflammation and serological response to C. pneumoniae in acute severe asthma. Subjects (n=54) were recruited within 4 h of presentation to the emergency department with an acute exacerbation of asthma. Clinical history taking, sputum induction (0.9% saline), spirometry and acute and convalescent serology for C. pneumoniae immunoglobulins A and G were performed. At presentation, 47% of subjects had antibodies directed against C. pneumoniae, and 38% (20) demonstrated an increase in C. pneumoniae antibody levels, with 15 demonstrating a rise in immunoglobulin A concentration. C. pneumoniae responders exhibited significantly higher sputum neutrophil levels (4.6 x 10(6) cells x mL(-1)) compared to nonresponders (1.2 x 10(6) cells x mL(-1), p=0.02) and elevated sputum eosinophil cationic protein concentration (3,981 versus 1,122 ng x mL(-1), p=0.02). An acute antibody response to Chlamydia pneumoniae is common in exacerbations of asthma. The serological features suggest that Chlamydia pneumoniae reactivation may trigger neutrophilic airway inflammation in acute asthma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12412672     DOI: 10.1183/09031936.02.00192002

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  17 in total

1.  Pathogenic bacteria and viruses in induced sputum or pharyngeal secretions of adults with stable asthma.

Authors:  T H Harju; M Leinonen; J Nokso-Koivisto; T Korhonen; R Räty; Q He; T Hovi; J Mertsola; A Bloigu; P Rytilä; P Saikku
Journal:  Thorax       Date:  2006-03-03       Impact factor: 9.139

Review 2.  Infection in severe asthma exacerbations and critical asthma syndrome.

Authors:  Christian E Sandrock; Andrew Norris
Journal:  Clin Rev Allergy Immunol       Date:  2015-02       Impact factor: 8.667

3.  Evaluation of lung function in pigs either experimentally or naturally infected with Chlamydiaceae.

Authors:  P Reinhold; J Jaeger; F Melzer; K Sachse
Journal:  Vet Res Commun       Date:  2005-03       Impact factor: 2.459

Review 4.  Pyroptosis-Induced Inflammation and Tissue Damage.

Authors:  Yinan Wei; Ling Yang; Ankit Pandeya; Jian Cui; Yan Zhang; Zhenyu Li
Journal:  J Mol Biol       Date:  2021-10-13       Impact factor: 5.469

5.  Unusual asthma syndromes and their management.

Authors:  Jaymin B Morjaria; Jack A Kastelik
Journal:  Ther Adv Chronic Dis       Date:  2011-07       Impact factor: 5.091

Review 6.  [Infections and asthma].

Authors:  G Rohde; J Rupp
Journal:  Internist (Berl)       Date:  2008-11       Impact factor: 0.743

7.  Interleukin-13 promotes susceptibility to chlamydial infection of the respiratory and genital tracts.

Authors:  Kelly L Asquith; Jay C Horvat; Gerard E Kaiko; Alison J Carey; Kenneth W Beagley; Philip M Hansbro; Paul S Foster
Journal:  PLoS Pathog       Date:  2011-05-05       Impact factor: 6.823

Review 8.  The role of antibiotics in asthma.

Authors:  Francesco Blasi; Sebastian L Johnston
Journal:  Int J Antimicrob Agents       Date:  2007-03-13       Impact factor: 5.283

9.  Severe asthma exacerbation: role of acute Chlamydophila pneumoniae and Mycoplasma pneumoniae infection.

Authors:  Roberto Cosentini; Paolo Tarsia; Ciro Canetta; Giovanna Graziadei; Anna Maria Brambilla; Stefano Aliberti; Maria Pappalettera; Francesca Tantardini; Francesco Blasi
Journal:  Respir Res       Date:  2008-05-30

Review 10.  Elucidating novel disease mechanisms in severe asthma.

Authors:  Richard Y Kim; Brittany Rae; Rachel Neal; Chantal Donovan; James Pinkerton; Lohis Balachandran; Malcolm R Starkey; Darryl A Knight; Jay C Horvat; Philip M Hansbro
Journal:  Clin Transl Immunology       Date:  2016-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.